Gapping up
In reaction to earnings/guidance:
- DOMO +20.5%, PD +15.6%, CLDR +12.6%, ZUO +5.7%, GCO +5%, DOCU +4.5%, SWBI +1.2%
Other news:
- STRO +23.5% (reports "encouraging" Interim data on STRO-002 Phase 1 study)
- BCRX +15.7% (receives FDA approval for ORLADEYO)
- CRTX +9.9% (Phase 2/3 GAIN trial of atuzaginstat (COR388) in patients with Alzheimer's disease successfully advances past interim analysis)
- DTIL +6.1% (reports positive interim results from PBCAR0191 phase 1/2a trial in relapsed/refractory (r/r) non-hodgkin lymphoma (NHL) and R/R B-cell acute lymphoblastic leukemia)
- CBIO +3.2% (to host call on systemic complement regulator programs)
- DMTK +3% (presents updates in precision medicine)
- TAK +2.6% (reports new Phase 3 data show TAK-620)
- CGNX +2.2% (declares special dividend of $2/sh)
- TTEC +2.2% (announces special dividend of $2.14/share)
- ZGNX +1.9% (enters into collaboration agreement with Tevard Biosciences)
- CSTL +1.9% (reports clinical impact of DecisionDx-Melanoma published in Future Oncology)
- GOL +1.4% (reports November traffic metrics)
- OC +1.2% (increases dividend; also authorizes 10 mln share repurchase program)
- SJM +1.2% (to sell its Natural Balance premium pet food business)
- MCK +1.1% (McKesson and Amgen (AMGN) launch strategic agreement to advance cancer innovation in communities)
- MRNA +1% (provides update on mRNA-1273; reaffirms expectation to have 20 mln doses in US by end of 2020)